Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Byron C. Scott, MD, MBA
Authored Items
90 Days in 2020: COVID-19 Exposes Health Equity Opportunities
Byron C. Scott, MD, MBA
September 2020 Vol 13, No 4
in
COVID-19
,
Perspectives
The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population
Byron C. Scott, MD, MBA
,
Nihar R. Desai, MD, MPH
,
Pamala Reed, DrPH, MPH
,
Paula J. Alvarez, RPh, MBA, MPH
,
Jeanene Fogli, PhD, RD
,
Steven D. Woods, PharmD
,
Mary Kay Owens, RPh, CPh
November 2019 Vol 12, No 7
in
Business
,
Original Research
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
Raghu Durvasula, MD, MHA
,
Byron C. Scott, MD, MBA
,
Janet Kelly, PharmD
,
Anneliese Schleyer, MD, MHA
,
Bradley D. Anawalt, MD
,
Shabir Somani, MS, MBA, RPh, FASHP
,
Timothy H. Dellit, MD
April 2018 Vol 11, No 2
in
Business
,
Review Article
Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Christopher B. Atzinger, MS, PhD candidate
,
Byron C. Scott, MD, MBA
,
Jeff J. Guo, BPharm, PhD
February 2017 Vol 10, No 1
in
Business
Bundled Payments: Value-Based Care Implications for Providers, Payers, and Patients
Byron C. Scott, MD, MBA
,
Tricia L. Eminger, MPH
December 2016 Vol 9, No 9
in
Industry Trends
Examining the Value of Subsidies of Health Plans and Cost-Sharing for Prescription Drugs in the Health Insurance Marketplace
Surachat Ngorsuraches, PhD
,
Byron C. Scott, MD, MBA
,
Jane R. Mort, PharmD
October 2016 Vol 9, No 7
in
Regulatory
Oncologist Support for Consolidated Payments for Cancer Care Management in the United States
Siva Narayanan, MSc
,
Byron C. Scott, MD, MBA
,
Emily Hautamaki, MPH
July 2016 Vol 9, No 5
in
Regulatory
Convergence in Healthcare: Providers, Employers, and Health Plans
Byron C. Scott, MD, MBA
April 2016 Vol 9, No 2
in
Editorial
Last modified: April 12, 2019